Medicine, Health & Food
Volume: 114 , Issue: 1 , December Published Date: 04 December 2022
Publisher Name: IJRP
Views: 444 , Download: 441 , Pages: 45 - 49
DOI: 10.47119/IJRP10011411220224182
Publisher Name: IJRP
Views: 444 , Download: 441 , Pages: 45 - 49
DOI: 10.47119/IJRP10011411220224182
Authors
# | Author Name |
---|---|
1 | Afkarina Norma Asilah |
2 | Rio Wironegoro |
3 | Nila Kurniasari |
Abstract
Graves disease is an autoimmune disorder affecting the thyroid gland with a wide range of clinical manifestations. One of the most notable signs of Graves disease is hyperthyroidism. In general, there are three options in treating Graves hyperthyroidism: pharmacological therapy, thyroidectomy, and radioactive iodine therapy. Thionamides, which consist of methimazole, carbimazole, and propylthiouracil, are considered to be the most prominent pharmacological therapy of Graves disease. Among these drugs, propylthiouracil is the least favored because of its adverse effects.